Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates

Table 1 Clinical characteristics and eradication rates of the two groups n (%)

		Group Awithout PPI pretreatment(n = 573)	Group Bwith PPI pretreatment(n = 517)	P value
Age	mean ± SD (yr)	51.8 ± 12.2	51.2 ± 13.4	0.453
Sex	Male	343 (59.9)	351 (67.9)	0.007
Diagnosis	Iatrogenic ulcer	31 (5.4)	107 (20.0)	< 0.001
	Peptic ulcer	438 (76.4)	395 (77.1)
	Non-ulcer disease	104 (18.2)	15 (2.9)
PPI in the eradication regimen	Lansoprazole 30 mg	439 (76.6)	410 (79.3)	0.021
	Esomeprazole 40 mg	92 (16.1)	56 (10.8)
	Rabeprazole 20 mg	42 (7.3)	51 (9.9)
Eradication assessment method	13C-urea breath test	525 (91.6)	408 (78.9)	< 0.001
	Rapid urease test	37 (6.5)	106 (20.5)
	Histological examination	11 (1.9)	3 (0.6)
Eradication rate		454 (79.2)	420 (81.2)	0.407

PPI: Proton pump inhibitors.

Table 2 Types of proton pump inhibitors used in the pretreatment in Group B n (%)

	Group B-I3-14 d (n = 146)	Group B-II15-55 d (n = 274)	Group B-III≥56 d (n = 97)	P value1
Lansoprazole	80 (54.8)	174 (63.5)	62 (63.9)	0.294
Rabeprazole	56 (38.4)	82 (29.9)	29 (29.9)
Esomeprazole	8 (5.5)	17 (6.2)	4 (4.1)
Omeprazole	2 (1.4)	1 (0.4)	2 (2.1)

¹Fisher’s exact test was used.